lorazepam has been researched along with Neuroleptic Malignant Syndrome in 34 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case of a male patient with schizophrenic illness who developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine is reported." | 7.75 | Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. ( Borkar, HA; Chandak, S; Srivastava, A, 2009) |
| "We present the case of a 14-year-old female who had many characteristics of neuroleptic malignant syndrome (NMS) without pyrexia following a single depot injection of 200 mg of zuclopenthixol." | 7.74 | Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. ( Bildik, T; Ercan, ES; Erermis, S; Gockay, A; Karasoy, H; Tamar, M, 2007) |
| "Neuroleptic-induced catatonia is reported in an adolescent patient who responded successfully to lorazepam." | 4.78 | Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. ( Woodbury, MA; Woodbury, MM, 1992) |
| "A case of a male patient with schizophrenic illness who developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine is reported." | 3.75 | Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. ( Borkar, HA; Chandak, S; Srivastava, A, 2009) |
| "We present the case of a 14-year-old female who had many characteristics of neuroleptic malignant syndrome (NMS) without pyrexia following a single depot injection of 200 mg of zuclopenthixol." | 3.74 | Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. ( Bildik, T; Ercan, ES; Erermis, S; Gockay, A; Karasoy, H; Tamar, M, 2007) |
| "An adult schizophrenic patient developed neuroleptic malignant syndrome following treatment with parenteral haloperidol." | 3.68 | Neuroleptic malignant syndrome (a case report). ( Patkar, AA; Shah, LP, 1991) |
| "Catatonia is a distinct neuropsychiatric syndrome that is becoming more recognized clinically and in ongoing research." | 2.46 | Catatonia: diagnosis, classification, and treatment. ( Francis, A, 2010) |
| "In the first, catatonia was described as an under-recognized syndrome with a potentially fatal outcome." | 2.40 | Catatonia. 2: Diagnosis, management and prognosis. ( Clark, T; Rickards, H, 1999) |
| "While neuroleptic malignant syndrome (NMS) is typically characterised by delirium, motor rigidity, fever and dysautonomia, the syndrome is not pathognomonic, and NMS remains a diagnosis of exclusion." | 1.51 | Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach. ( Barahona-Corrêa, JB; Neves, A; Oliveira-Maia, AJ; Velosa, A, 2019) |
| "Malignant catatonia is a severe form of catatonia which is acute in onset, and is systemically devastating, as it is associated with fever and autonomic instability." | 1.35 | Electroconvulsive therapy for malignant catatonia in adolescence. ( Burt, L; Dhossche, DM; Kumar, T; Shettar, SM, 2009) |
| "Two patients with the neuroleptic malignant syndrome (NMS), a man aged 31 years and a woman aged 83 years, were referred for electroconvulsive therapy after 70 and 7 days, respectively." | 1.33 | [Neuroleptic malignant syndrome: a life-threatening complication that can be treated effectively]. ( Muller, ME; van Waarde, JA; Verweg, B, 2006) |
| "Lorazepam was used as initial treatment, which provided significant improvement." | 1.32 | A malignant neuroleptic spectrum: review of diagnostic criteria and treatment implications in three case reports. ( Pandya, M; Pozuelo, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 16 (47.06) | 29.6817 |
| 2010's | 8 (23.53) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandez, A | 1 |
| Pendaries, G | 1 |
| Dor, E | 1 |
| Askenazy, F | 1 |
| Thümmler, S | 1 |
| Das, S | 1 |
| Purushothaman, ST | 1 |
| Bc, M | 1 |
| Chatterjee, SS | 1 |
| Kartha, A | 1 |
| Rajan, V | 1 |
| Hardman, MI | 1 |
| Sprung, J | 1 |
| Weingarten, TN | 1 |
| Velosa, A | 1 |
| Neves, A | 1 |
| Barahona-Corrêa, JB | 1 |
| Oliveira-Maia, AJ | 1 |
| Lopez, E | 1 |
| Fraile, S | 1 |
| Hidalgo, FJ | 1 |
| García, B | 1 |
| Verma, R | 1 |
| Junewar, V | 1 |
| Rathaur, BP | 1 |
| Guru, S | 1 |
| Vanamoorthy, U | 1 |
| Loganathan, S | 1 |
| Varghese, M | 1 |
| Rosebush, PI | 1 |
| Anglin, RE | 1 |
| Richards, C | 1 |
| Mazurek, MF | 1 |
| Srivastava, A | 1 |
| Borkar, HA | 1 |
| Chandak, S | 1 |
| Brantley, E | 1 |
| Cohn, J | 1 |
| Babu, K | 1 |
| Ghio, L | 1 |
| Fornaro, G | 1 |
| Rossi, P | 1 |
| Dhossche, DM | 1 |
| Shettar, SM | 1 |
| Kumar, T | 1 |
| Burt, L | 1 |
| Francis, A | 1 |
| Coffey, MJ | 1 |
| Chakraborty, N | 1 |
| Johnston, T | 1 |
| Pandya, M | 1 |
| Pozuelo, L | 1 |
| Mendhekar, DN | 1 |
| Jiloha, RC | 1 |
| Hammerman, S | 1 |
| Lam, C | 1 |
| Caroff, SN | 2 |
| van Waarde, JA | 1 |
| Muller, ME | 1 |
| Verweg, B | 1 |
| Erermis, S | 1 |
| Bildik, T | 1 |
| Tamar, M | 1 |
| Gockay, A | 1 |
| Karasoy, H | 1 |
| Ercan, ES | 1 |
| Strawn, JR | 1 |
| Keck, PE | 1 |
| Khan, KH | 1 |
| Tham, TC | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Real Rodríguez, B | 1 |
| Ruibal, JL | 1 |
| Grande Rodríguez, S | 1 |
| Sueiro Pita, B | 1 |
| Fink, M | 1 |
| Lausberg, H | 1 |
| Hellweg, R | 1 |
| Clark, T | 1 |
| Rickards, H | 1 |
| Duggal, HS | 1 |
| Hatch, CD | 1 |
| Lund, BC | 1 |
| Perry, PJ | 1 |
| Woodbury, MM | 1 |
| Woodbury, MA | 1 |
| Weller, M | 1 |
| Patkar, AA | 1 |
| Shah, LP | 1 |
| Chandler, JD | 1 |
| Ryken, TC | 1 |
| Merrell, AN | 1 |
6 reviews available for lorazepam and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor | 2019 |
Catatonia: diagnosis, classification, and treatment.
Topics: Anticonvulsants; Catatonia; Diagnosis, Differential; Diagnostic and Statistical Manual of Mental Dis | 2010 |
Neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Dantr | 2007 |
[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam].
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipsychot | 1996 |
Catatonia. 2: Diagnosis, management and prognosis.
Topics: Benzodiazepines; Catatonia; Diagnosis, Differential; Electroconvulsive Therapy; Humans; Hypnotics an | 1999 |
Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.
Topics: Adolescent; Catatonia; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Male; Neuroleptic | 1992 |
28 other studies available for lorazepam and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
[Malignant neuroleptic syndrome: An atypical case in an adolescent affected by bipolar I disorder associated with catatonic syndrome].
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Catatonia; Electroencephalography; Humans; Hypno | 2020 |
Oral Asenapine overdose leading to Neuroleptic Malignant Syndrome (NMS).
Topics: Administration, Oral; Adult; Antipsychotic Agents; Bromocriptine; Diagnosis, Differential; Dibenzocy | 2017 |
Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach.
Topics: Acute Kidney Injury; Adult; Anticonvulsants; Antipsychotic Agents; Bromocriptine; Diagnosis, Differe | 2019 |
[Possible malignant neuroleptic syndrome associated with aripiprazole and imipramine and treated with bromocriptine].
Topics: Antipsychotic Agents; Aripiprazole; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combinat | 2013 |
An atypical case of neuroleptic malignant syndrome precipitated by valproate.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Dopamine Agonists; Drug Ther | 2014 |
Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Female; Humans; Lorazepam; Neuroleptic Malignant Synd | 2014 |
Neuroleptic malignant syndrome and the acute phase response.
Topics: Acute-Phase Proteins; Acute-Phase Reaction; Adolescent; GABA Modulators; Humans; Lorazepam; Male; Ne | 2008 |
Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Consciousness; Humans; Hypnotics and Sedatives; Lorazepam; Ma | 2009 |
Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Fluid | 2009 |
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report.
Topics: Antipsychotic Agents; Female; Humans; Hyperamylasemia; Injections, Intramuscular; Intubation, Gastro | 2009 |
Electroconvulsive therapy for malignant catatonia in adolescence.
Topics: Adolescent; Anti-Anxiety Agents; Catatonia; Diagnosis, Differential; Electroconvulsive Therapy; Huma | 2009 |
Catatonia and encephalopathy associated with paliperidone palmitate.
Topics: Aged; Antipsychotic Agents; Catatonia; Female; Humans; Isoxazoles; Lorazepam; Male; Neuroleptic Mali | 2012 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male | 2004 |
A malignant neuroleptic spectrum: review of diagnostic criteria and treatment implications in three case reports.
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Female; GABA Modulators; Humans; Lorazepam; | 2004 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Cr | 2005 |
Neuroleptic malignant syndrome and aripiprazole.
Topics: Adolescent; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder; Female; Hu | 2006 |
[Neuroleptic malignant syndrome: a life-threatening complication that can be treated effectively].
Topics: Adult; Aged, 80 and over; Electroconvulsive Therapy; Female; Humans; Hypnotics and Sedatives; Loraze | 2006 |
Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl.
Topics: Adolescent; Anti-Anxiety Agents; Antidotes; Antipsychotic Agents; Bromocriptine; Clopenthixol; Delay | 2007 |
Neuroleptic malignant syndrome induced by quetiapine overdose.
Topics: Acetaminophen; Antidotes; Antipsychotic Agents; Dibenzothiazepines; Drug Overdose; Female; Humans; L | 2008 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Toxic serotonin syndrome or neuroleptic malignant syndrome?
Topics: Antidepressive Agents, Tricyclic; Central Nervous System Diseases; Electroconvulsive Therapy; Female | 1996 |
["Catatonic dilemma". Therapy with lorazepam and clozapine].
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Diagnosis, Differential; Drug Therapy, | 1998 |
Neuroleptic malignant syndrome precipitated by promethazine and lorazepam.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Basal Ganglia Diseases; Histamine H1 Antagonists; | 2001 |
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.
Topics: Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Dibenzothiazepines; Haloperidol; Humans; Hy | 2001 |
NMS and lethal catatonia.
Topics: Catatonia; Clozapine; Diagnosis, Differential; Humans; Lorazepam; Neuroleptic Malignant Syndrome | 1992 |
Neuroleptic malignant syndrome (a case report).
Topics: Adult; Bromocriptine; Female; Haloperidol; Humans; Lorazepam; Neuroleptic Malignant Syndrome | 1991 |
Psychogenic catatonia with elevated creatine kinase and autonomic hyperactivity.
Topics: Adult; Arousal; Autonomic Nervous System; Catatonia; Combined Modality Therapy; Creatine Kinase; Del | 1991 |
Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism.
Topics: Aged; Female; Haloperidol; Humans; Lorazepam; Neuroleptic Malignant Syndrome; Parkinson Disease | 1989 |